PAXMEDICA INC (PXMD) Stock Price, Forecast & Analysis
USA - NASDAQ:PXMD - US70424C2035 - Common Stock
PXMD Key Statistics, Chart & Performance
The current stock price of PXMD is 0.6883 USD. In the past month the price increased by 27.7%. In the past year, price decreased by -97.28%.
PXMD Latest News, Press Relases and Analysis
PXMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.8 | 953.22B | ||
| JNJ | JOHNSON & JOHNSON | 18.68 | 467.03B | ||
| MRK | MERCK & CO. INC. | 10.39 | 228.70B | ||
| PFE | PFIZER INC | 7.97 | 145.07B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.55 | 100.77B | ||
| ZTS | ZOETIS INC | 19.16 | 53.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.63 | 23.09B | ||
| VTRS | VIATRIS INC | 4.75 | 12.90B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.66 | 11.29B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.15 | 8.36B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.00B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.53 | 4.08B |
Related stock screener links
About PXMD
Company Profile
PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
Company Info
PAXMEDICA INC
303 South Broadway, Suite 125
Tarrytown NEW YORK US
Employees: 3
Phone: 19149872876
PAXMEDICA INC / PXMD FAQ
What does PAXMEDICA INC do?
PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
What is the stock price of PAXMEDICA INC today?
The current stock price of PXMD is 0.6883 USD. The price decreased by -7.61% in the last trading session.
Does PXMD stock pay dividends?
PXMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of PXMD stock?
PXMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for PAXMEDICA INC?
PAXMEDICA INC (PXMD) has a market capitalization of 5.10M USD. This makes PXMD a Nano Cap stock.
Who owns PAXMEDICA INC?
You can find the ownership structure of PAXMEDICA INC (PXMD) on the Ownership tab.
PXMD Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PXMD. When comparing the yearly performance of all stocks, PXMD is a bad performer in the overall market: 88.21% of all stocks are doing better.
PXMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PXMD. While PXMD seems to be doing ok healthwise, there are quite some concerns on its profitability.
PXMD Financial Highlights
Over the last trailing twelve months PXMD reported a non-GAAP Earnings per Share(EPS) of -15.85. The EPS increased by 23.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -321.98% | ||
| ROE | -540.3% | ||
| Debt/Equity | 0 |
PXMD Forecast & Estimates
null analysts have analysed PXMD and the average price target is 3.06 USD. This implies a price increase of 344.57% is expected in the next year compared to the current price of 0.6883.